An official website of the United States government
Home
Name
Devimistat
Alternate Names
CPI-613
Alpha-Lipoic Acid Analogue CPI-613
Abbreviations
None
Category
Other therapy
Subcategory
None
NSC Number
None
Primary Site
Soft tissue
Histology
None
Remarks
January 8, 2021 FDA has granted Fast Track designation to CPI-613 (devimistat) for the treatment of acute myeloid leukemia.
October 30, 2020: CPI-613 (devimistat) received Orphan Drug designation from FDA for the treatment of soft tissue sarcoma
IMPORTANT NOTE: Per FDA and NCI, devistate is a mixture of the enantiomers of a synthetic alpha-lipoic lipoic acid analogue with potential chemopreventive and antineoplastic activities. Although the exact mechanism of action is unknown, devimistat has been shown to inhibit metabolic and regulatory processes required for cell growth in solid tumors. Both enantiomers in the racemic mixture exhibit antineoplastic activity. This drug has not been classified as chemotherapeutic or immunotherapy.
October 30, 2020: CPI-613 (devimistat) received Orphan Drug designation from FDA for the treatment of soft tissue sarcoma
IMPORTANT NOTE: Per FDA and NCI, devistate is a mixture of the enantiomers of a synthetic alpha-lipoic lipoic acid analogue with potential chemopreventive and antineoplastic activities. Although the exact mechanism of action is unknown, devimistat has been shown to inhibit metabolic and regulatory processes required for cell growth in solid tumors. Both enantiomers in the racemic mixture exhibit antineoplastic activity. This drug has not been classified as chemotherapeutic or immunotherapy.
Coding
This drug should be coded
